Head to head
Epitalon vs NAD+
Two compounds, one grading system.
On human evidence, NAD+ currently leads: emerging versus limited evidence.
01
At a glance
EpitalonLimited evidence
Soviet-era longevity peptide. Claims far exceed independently replicated evidence.
101publications
0RCTs
NAD+Emerging
A coenzyme, not a peptide. Precursors have better human data than NAD+ itself.
14publications
2RCTs
02
Side by side
| Attribute | Epitalon | NAD+ |
|---|---|---|
| Goal | Longevity | Longevity |
| Evidence | Limited evidence | Emerging |
| Publications | 101 | 14 |
| Randomised trials | 0 | 2 |
| Sport (WADA) | S0 — prohibited | — |
| US compounding | PCAC-voted for 503A review | — |
03
Claims vs data
Epitalon — claims vs data
| Extends human lifespan | overreach |
| Activates telomerase | weak evidence |
NAD+ — claims vs data
| Oral precursors raise NAD+ levels | supported |
| Slows human ageing | weak evidence |
| IV NAD+ is better studied than oral precursors | overreach |